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total of 84 active ingredients had new indications or label changes. After removal of 
25 duplicate ingredients (or updated again during this timeframe), 59 labels and IFs 
were identified and reviewed. No product labels contained PRO information. However, 
in contrast 20 (34%) IFs contained PRO information. 10 of these IFs only stated that 
“QOL” or “PRO” was assessed without details on the questionnaires or results. The 
EORTC (European Organisation for Research and Treatment of Cancer) and FACT 
(Functional Assessment of Cancer Therapy) were explicitly stated as measures in 
four and three IFs, respectively. There were also three pain assessments; two Visual 
Analog Scale assessments and one utilizing the Brief Pain Inventory – Short Form 
(BPI-SF). ConClusions: Although no oncology labels contained PRO information, 
the IFs contained PRO information. 1/3 of product information contained a mention 
of PROs which can be used in discussions with clinicians.
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objeCtives: To explore changes in child-reported quality of life (QOL) of pediatric 
leukemia/lymphoma patients receiving alloSCT. Methods: Hierarchical linear 
modeling was used to explore trends in select PedsQL 4.0 sub-scales and individual 
items of 43 children ≥ 5 years of age. QOL was assessed once pre-alloSCT and on 
days 100, 180, 365, and 730, post-alloSCT. Results: Median age: 13.54 years, Range: 
4.66-23.12 years; leukemia: 76.7%; lymphoma: 23.3%; reduced-toxicity conditioning 
(RTC)/myeloablative conditioning (MAC): 44%/56%; chronic graft-versus-host disease 
(cGVHD): 27.9%. Emotional and social functioning was stable pre-to-post-alloSCT 
and comparable to a normative pediatric sample (p> .05), whereas physical func-
tioning was 19 points lower pre-alloSCT (M= 67.42; p< .01; ES= 1.26SD) with improved 
scores approaching norms by Day +730. 51-65% of children at baseline reported dif-
ficulties with sports/exercise, strength, pain, and fatigue. Significant improvements 
from baseline (M= 51.41) were observed in sports/exercise at a rate of 1.06 points-
per-month (ppm)/12.90 points-per-year (ppy) (t= 2.57; p= .01) and strength (M= 47.47; 
t= 2.05; p= .04) at a rate of 0.84 ppm (10.21ppy). Recipients of RTC significantly 
improved at a rate of 14.04ppy (slope= 1.16; t= 2.41; p= .02) compared to children who 
received MAC (-4.01ppy; slope= -0.33). Similarly gains in strength were significantly 
better for the RTC group (12.94ppy; slope= 1.06; t= 2.25; p= .02) than the MAC group 
(-10.62ppy; slope= -0.83). Levels of pain (M= 64.82; slope= 0.05ppm; t= 0.15; p= .88) and 
fatigue (M= 58.01; slope= 0.39ppm; t= 1.14; p= .26) remained unchanged irrespective 
of conditioning regimen. Emotional functioning of children ages 8-12 significantly 
improved from baseline (M= 70.18; slope= 1.78ppm; t= 2.89; p= .01), whereas children 
≥ 13 significantly declined post-alloSCT (M= 72.61; slope= -1.34ppm; t= -2.64; p= .01). 
Presence of cGVHD did not significantly affect outcomes scores. ConClusions: 
Improvements in exercise and strength were seen with RTC regimens whereas 
pain and fatigue remained unchanged independent of conditioning regimen. Older 
children may have more emotional difficulties post-alloSCT. These results highlight 
the importance of including QOL to monitor patients and further define outcomes 
for this population.
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objeCtives: To assess quality of life of Polish patients with a stoma using validated 
generic questionnaire. Methods: Adult patients with colostomy, ileostomy or uro-
stomy performed in Poland between July 2009 and December 2010 were included. 
Patients completed satisfaction survey at the discharge from the hospital, and The 
World Health Organization Quality of Life-BREF (WHOQOL-BREF) generic question-
naire at 3 months after surgery. Results: The study involved 1519 patients (71.5%, 
16.8%, 11.7% with colostomy, ileostomy and urostomy, respectively). The studied 
population was highly diversified in terms of: pain and discomfort, dependence on 
medical treatment and acceptance of physical appearance. 57% of patients with a 
stoma defined their quality of life as good or very good (mean 3.54 points; range: 
1 to 5; SD 0.73). The subjects were characterized by low quality of life assessment 
in the physical health and psychological domains (53.5 and 60.0 pts.) and by high 
evaluation in the environment and social relationships domains (69.6 and 70.2 pts.). 
Respondents highly assessed: the level of social support, home environment, physi-
cal environment, personal relationships. Low assessment was related to: sexual 
activity, ability to work, dependence on medical treatment, financial resources, 
satisfaction with health. ConClusions: This is the first Polish study on the quality 
of life of patients with a stoma, based on validated generic questionnaire. The results 
should help improve standards of care for patients with a stoma.
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objeCtives: To assess the impact of anxiety and depression measured by Hospital 
Anxiety and Depression Scale (HADS) on 1-year HRQoL measured by EuroQol-3L (EQ-
5D) and EORTC-QLQ-C30 on patients with colorectal cancer.This aspect of continuity 
tions, year, PRO instrument, and results for PROs. Analysis was conducted to identify 
trends in commonly used PRO instruments and results were categorized as posi-
tive, neutral, or negative. Results: Eight RCTs with a total of 3,342 patients were 
identified. In these studies, there were eight different PROs instruments identified: 
FACT-Leu, SF-36, FSI, PSQI, MSAS-SF, FACT-BRM, EQ-5D, and MDASI-CML. The most 
commonly used instruments were FACT-Leu (used in 1,336 patients) and FACT-BRM 
(used in 1,199 patients). Five studies reported positive results with improvement in 
quality of life (QoL) symptoms versus comparator treatments. Two studies reported 
results highlighting significant deterioration in QoL versus patients with no cancer. 
One study reported QoL in various types of CML and showed significant deterioration 
in patients with chronic phase CML versus those with acute and blast phase CML. 
Studies also identified two QoL domains, depression and fatigue, which matter most 
for patients with CML. ConClusions: Patients with CML have significant deterio-
ration in their QoL. PRO instruments such as FACT-Leu and FACT-BRM can aid in 
generating evidence to show which therapies improve patient QoL.
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objeCtives: Patient reported outcomes (PRO) are becoming useful tools for col-
lecting and generating evidence for new medical products to show improvements 
in health-related quality of life (HRQoL). Castration-Resistant Prostate Cancer 
(CRPC) is a chronic disease with high importance for patient HRQoL. The objective 
of this study was to review, analyze, and understand trends in the PRO instruments 
used in patients with CRPC. Methods: A systematic literature search for CRPC 
randomized controlled trials (RCTs) with PROs endpoints was undertaken for the 
databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was col-
lected for the study size, interventions, year, PRO instrument, and results for PROs. 
Analysis was conducted to identify trends in commonly used PRO instruments 
and categorize results as positive, neutral or negative. Results: Ten RCTs with 
a total of 5,797 patients were identified. In these studies there were thirteen dif-
ferent PROs instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, 
EQPR25, FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most 
commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 (used 
in 1,091 patients). Six studies reported positive results with improvement in qual-
ity of life symptoms (QoL) versus comparator treatments. Fours studies reported 
results with deterioration in (QOL). Three studies reported improvement in pain 
scores. ConClusions: Patients with CRPC have relatively longer survival and 
hence QoL is an important consideration for these patients. PRO instruments such 
as FACT-P and EQC-30 have been commonly used to generate evidence to show 
which therapies improve patient QoL.
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objeCtives: Feeling “dizzy” or “lightheaded” are common concepts in patient-reported 
outcome (PRO) instruments in a number of conditions. The Functional Assessment of 
Cancer Therapy – Anemia (FACT-An) subscale contains an item assessing “feeling dizzy 
(lightheaded)” as one concept while other instruments propose to assess the symptoms 
as two separate concepts or items. The purpose of this study was to translate and assess 
conceptual equivalence of this concept across 20 languages (21 countries). Methods: 
The FACT-An was translated following the FACIT Translation methodology which is 
consistent with ISPOR guidelines for translation and cultural adaptation of PRO 
measures (Wild et al., 2005). The translation process for each language consisted of: 2 
forward translations by native translators, reconciliation of the forward translations, 
1 back-translation by an English-speaker fluent in the target language, 3 reviews by 
native translators or clinicians, final reconciliation by a native speaking linguist, and 
harmonization. Interviews were conducted among 456 native-speaking patients in 21 
countries. Data were analyzed to assess linguistic and cultural validity of the FACT-An in 
each language and confirm conceptual equivalence. Results: Mean age of the sample 
(N= 456) was 55 years, (range 19-88) and 58% were male. During the translation phase, 12 
of the 20 languages translated the concept of dizzy (lightheaded) using only one term, 
and the remaining 8 languages provided two terms. The rationale was that one word 
was used to describe this set of symptoms and it would be a complicated explanation 
to address the second term. The translations were well understood and considered rel-
evant. ConClusions: The majority of languages in this study provided only one term 
for the concept of dizzy (lightheaded) indicating that it may be problematic to assess 
the concept as two separate symptoms in future questionnaires in other languages 
where this concept is not separated as it is in English.
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objeCtives: There is a growing use of patient-reported outcomes (PRO) in the US 
and Europe but little is known about Asia. Oncology in particular is an area of growing 
interest. This study sought to review PRO labeling within oncology products over the 
last five years in Japan. Methods: Oncology labels were identified by reviewing the 
Pharmaceutical and Medical Devices Agency (PMDA) postings of label changes for 
the past 5 years (2007-2012). For identified products with label changes, labels and 
Interview Forms (IF) were acquired and reviewed. The IF is used as a supplement to 
the label in Japan to provide additional data that will not fit within the package insert. 
Only PROs used for potential promotion were evaluated. Symptoms such as pain listed 
in the adverse events or safety sections were not included in this review. Results: A 
